Comparing Cancer Genetics (CGIX) & Its Competitors

Cancer Genetics (NASDAQ:CGIX) is one of 49 public companies in the “Medical Laboratories” industry, but how does it contrast to its peers? We will compare Cancer Genetics to similar companies based on the strength of its valuation, earnings, analyst recommendations, risk, profitability, institutional ownership and dividends.

Risk & Volatility

Cancer Genetics has a beta of 2.72, meaning that its share price is 172% more volatile than the S&P 500. Comparatively, Cancer Genetics’ peers have a beta of 1.00, meaning that their average share price is 0% less volatile than the S&P 500.

Profitability

This table compares Cancer Genetics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cancer Genetics	N/A	N/A	N/A
Cancer Genetics Competitors	-1,439.22%	-368.95%	-41.75%

Institutional & Insider Ownership

8.9% of Cancer Genetics shares are held by institutional investors. Comparatively, 44.9% of shares of all “Medical Laboratories” companies are held by institutional investors. 15.0% of Cancer Genetics shares are held by company insiders. Comparatively, 21.6% of shares of all “Medical Laboratories” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Cancer Genetics and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cancer Genetics	$6.33 million	N/A	-0.08
Cancer Genetics Competitors	$712.49 million	-$139.13 million	-3.32

Cancer Genetics’ peers have higher revenue, but lower earnings than Cancer Genetics. Cancer Genetics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings for Cancer Genetics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cancer Genetics	0	0	0	0	N/A
Cancer Genetics Competitors	244	908	1851	29	2.55

As a group, “Medical Laboratories” companies have a potential upside of 41.47%. Given Cancer Genetics’ peers higher possible upside, analysts plainly believe Cancer Genetics has less favorable growth aspects than its peers.

Summary

Cancer Genetics beats its peers on 5 of the 9 factors compared.

About Cancer Genetics

Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson’s Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.